We are a privately held medical technology company focused on designing and creating innovative and easy to use rapid diagnostics technologies.
We aim to use cutting-edge technologies and integrative disease management systems to address and eliminate inefficiencies in rapid testing: making the rapid testing process and experience quicker and more convenient for all stakeholders involved.
Chief Executive Officer
Danisa holds a BSc (Eng) from Wits University and a Masters of Management from Antwerp Management School. She has international experience on the broader African continent as a strategy consultant, and currently has a special focus on innovation and strategy. She has experience in launching corporate ventures, making her ideal for this role. Danisa is passionate about making a difference through access to healthcare for all and believes that the technologies being developed by Incitech are key in driving this difference.
Chief Financial Officer
Lindiwe holds a BBusSc -Finance and Accounting (Hons) from the University of Cape Town. She has experience in investments, taxation and financial management. What drives Lindiwe is the desire to see all South Africans having equal access to quality healthcare, education of a high standard and equal employment opportunities.
Head of R&D
Loretta holds a BSc in Biochemistry, Cell Biology and Physiology from Wits University, a BSc(Hons) in Biotechnology from the University of Pretoria and an MSc in Clinical Science & Immunology from the University of Cape Town. She is currently pursuing a PhD in Medical Biochemistry from the University of Cape Town, which focuses is on using bioinformatics and imaging tools for cheaper, and quicker diagnosis of cancer. Her scientific career, thus far, has been primarily focused on gene expression within the context of infectious and non-communicable diseases. Her primary aspiration is to contribute to the improvement of African-epidemic infectious diseases, namely HIV and TB, diagnosis that will subsequently lead to a reduction of disease incidence by creating revolutionary yet simplistic point-of-care and self-diagnostic testing technologies.